If I am seriously ill with Covid19 I am heading to the DuPage co Northwestern hospital. If I go elsewhere there is almost a 100% chance of receiving Remdesivir which has been shown to have next to no effect on mortality or Covid complications.
Plus, we know Rememdesivir has been shown to have the potential to have hepatotoxicity since the current dose is close to the safe therapeutic index...a ratio that compares the blood concentration at which a drug becomes toxic and the concentration at which the drug is effective.
Remdesivir's hepatotoxicity was first described in the Ebola studies and is now being reported in Covid 19 patients being treated with Remdesivir.
Below are several recent reports of Covid19 patients suffering liver damage due to Remdesivir.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386240/
"Our observation supports previous findings obtained in healthy volunteers (Gilead Sciences, data on file) and COVID-19 patients treated with RDV [4, 5], suggesting this antiviral may cause hepatocellular injury."
In addition Remdesivir has many drug interactions which can limit treatment of other life threatening conditions:
https://academic.oup.com/cid/advance-article/...83/5864408
https://www.uptodate.com/contents/image/print...e=see_link
The argument that Brilacidin may have "known Serious Adverse Events" pales to the risk of Remdesivir. If a patients on Brilacidin has an increase in blood pressure increases it is easily treatable and serious elevations of blood pressure were not demonstrated at the Brilacidin.6mg/kg dose. The tingling sensation has not been shown to be associated with neurologic or other long term complications.
The real question is would you rather have a drug with the potential to have profound effect against Covid19 or a drug we know has little effect.
I will stand by my comments..
My bet is after Brilacidin's Phase2 trial there will be many requests across the country for compassionate use of Brilacidin for Covid 19 for the reasons I have outlined.
GLTA Farrell
Plus, we know Rememdesivir has been shown to have the potential to have hepatotoxicity since the current dose is close to the safe therapeutic index...a ratio that compares the blood concentration at which a drug becomes toxic and the concentration at which the drug is effective.
Remdesivir's hepatotoxicity was first described in the Ebola studies and is now being reported in Covid 19 patients being treated with Remdesivir.
Below are several recent reports of Covid19 patients suffering liver damage due to Remdesivir.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386240/
"Our observation supports previous findings obtained in healthy volunteers (Gilead Sciences, data on file) and COVID-19 patients treated with RDV [4, 5], suggesting this antiviral may cause hepatocellular injury."
In addition Remdesivir has many drug interactions which can limit treatment of other life threatening conditions:
https://academic.oup.com/cid/advance-article/...83/5864408
https://www.uptodate.com/contents/image/print...e=see_link
The argument that Brilacidin may have "known Serious Adverse Events" pales to the risk of Remdesivir. If a patients on Brilacidin has an increase in blood pressure increases it is easily treatable and serious elevations of blood pressure were not demonstrated at the Brilacidin.6mg/kg dose. The tingling sensation has not been shown to be associated with neurologic or other long term complications.
The real question is would you rather have a drug with the potential to have profound effect against Covid19 or a drug we know has little effect.
I will stand by my comments..
My bet is after Brilacidin's Phase2 trial there will be many requests across the country for compassionate use of Brilacidin for Covid 19 for the reasons I have outlined.
GLTA Farrell
9
1
